drugset / Trial / NCT06956170
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).
Timeline
- Start
- 2022-02-10
- Primary completion
- 2024-05-27
- Completion
- 2029-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | — | — |
| Comparator | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |